{
    "clinical_study": {
        "@rank": "99357", 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone\n      or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related\n      Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free\n      survival and quality of life.\n\n      Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors,\n      which permits disease palliation at relatively low doses and thus decreases some of the\n      dose-limiting toxicity.  Multi-agent therapy is considered to be more effective than\n      single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine."
        }, 
        "brief_title": "Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS", 
        "completion_date": {
            "#text": "August 1998", 
            "@type": "Actual"
        }, 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors,\n      which permits disease palliation at relatively low doses and thus decreases some of the\n      dose-limiting toxicity.  Multi-agent therapy is considered to be more effective than\n      single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.\n\n      Patients are randomized to receive intravenous DOX-SL alone or in combination with\n      vincristine/bleomycin every 2 weeks. Filgrastim ( granulocyte colony-stimulating factor;\n      G-CSF ) may be given as needed for neutropenia.\n\n      AS PER AMENDMENT 11/7/96: Based on interim review data, it is recommended that subjects\n      receiving DOX-SL plus vincristine/bleomycin have vincristine/bleomycin discontinued and\n      receive DOX-SL alone unless, in the opinion of the treating physician, they are benefitting\n      from the DOX-SL plus vincristine/bleomycin regimen."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  G-CSF.\n\n          -  Licensed or Treatment IND-approved antiretrovirals ( AZT, ddI, ddC, d4T ).\n\n          -  PCP prophylaxis (required if CD4 count < 200 cells/mm3).\n\n          -  Chemoprophylaxis or maintenance for bacterial infections, candidiasis, MAC, and\n             herpes simplex.\n\n          -  Up to 14 days of metronidazole.\n\n          -  Recombinant erythropoietin.\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  Advanced stage Kaposi's sarcoma.\n\n          -  No active acute opportunistic infection.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Significant pulmonary insufficiency (unless due to pulmonary KS).\n\n          -  Significant cardiac insufficiency.\n\n          -  Other active malignancies except for basal or squamous cell carcinoma of the skin or\n             in situ cervical cancer.\n\n          -  Grade 2 or worse peripheral neuropathy.\n\n          -  Altered mental status that prevents informed consent.\n\n          -  Active Mycobacterium tuberculosis.\n\n          -  Hypersensitivity or allergic reaction to any study drugs or E. coli-derived\n             medications such as filgrastim (G-CSF).\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  GM-CSF.\n\n          -  Drugs associated with peripheral neuropathy (other than approved antiretrovirals and\n             vincristine).\n\n          -  Multi-drug therapy for active Mycobacterium tuberculosis (although isoniazid and\n             pyridoxine is allowed as treatment for a positive PPD, with permission of study\n             chair).\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy to study marker lesions.\n\n        Patients with the following prior condition are excluded:\n\n          -  Neuropsychiatric history.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any anti-KS therapy within 21 days prior to study entry.\n\n          -  Prior systemic therapy with any anthracycline (including liposomal anthracyclines),\n             vincristine, or bleomycin.\n\n          -  Any investigational drug (other than those available through Treatment IND and used\n             for FDA-sanctioned purposes) within 14 days prior to study entry.\n\n        PER AMENDMENT 11/29/95:\n\n          -  No more than 2 cycles of any systemic chemotherapy for Kaposi's sarcoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001059", 
            "org_study_id": "ACTG 286", 
            "secondary_id": "11262"
        }, 
        "intervention": [
            {
                "intervention_name": "Doxorubicin hydrochloride (liposomal)", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Filgrastim", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Bleomycin sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Vincristine sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bleomycin", 
                "Doxorubicin", 
                "Vincristine", 
                "Lenograstim"
            ]
        }, 
        "keyword": [
            "Vincristine", 
            "Sarcoma, Kaposi", 
            "Liposomes", 
            "Doxorubicin", 
            "Drug Therapy, Combination", 
            "Granulocyte Colony-Stimulating Factor", 
            "Acquired Immunodeficiency Syndrome", 
            "Bleomycin", 
            "Drug Carriers"
        ], 
        "lastchanged_date": "April 13, 2012", 
        "link": {
            "description": "Click here for more information about Doxorubicin hydrochloride (liposomal)", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=185"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Alabama Therapeutics CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA CARE Center CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Ucsf Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "University of Colorado Hospital CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Univ. of Miami AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96816"
                    }, 
                    "name": "Univ. of Hawaii at Manoa, Leahi Hosp."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96813"
                    }, 
                    "name": "Queens Med. Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Univ. Med. Ctr. ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana Univ. School of Medicine, Infectious Disease Research Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess - East Campus A0102 CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Bmc Actg Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Massachusetts General Hospital ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington U CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14215"
                    }, 
                    "name": "SUNY - Buffalo, Erie County Medical Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Ctr."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Comparison Study of Liposomal Doxorubicin With or Without Bleomycin and Vincristine for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma", 
        "overall_official": [
            {
                "last_name": "Mitsuyasu R", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Krown S", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Von Roenn JH", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "citation": "Mitsuyasu R, et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi's sarcoma (AIDS-KS): AIDS Clinical Trial Group (ACTG) protocol 286 (meeting abstract). Proc Annu Meet Am Soc Clin Oncol. 1997;16:A191"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001059"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Sequus Pharmaceuticals", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Amgen", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Alabama Therapeutics CRS": "33.521 -86.802", 
        "Beth Israel Deaconess - East Campus A0102 CRS": "42.358 -71.06", 
        "Bmc Actg Crs": "42.358 -71.06", 
        "Indiana Univ. School of Medicine, Infectious Disease Research Clinic": "39.769 -86.158", 
        "Massachusetts General Hospital ACTG CRS": "42.358 -71.06", 
        "Memorial Sloan-Kettering Cancer Ctr.": "40.714 -74.006", 
        "Northwestern University CRS": "41.878 -87.63", 
        "Queens Med. Ctr.": "21.307 -157.858", 
        "Rush Univ. Med. Ctr. ACTG CRS": "41.878 -87.63", 
        "SUNY - Buffalo, Erie County Medical Ctr.": "42.886 -78.878", 
        "UCLA CARE Center CRS": "34.052 -118.244", 
        "USC CRS": "34.052 -118.244", 
        "Ucsf Aids Crs": "37.775 -122.419", 
        "Univ. of Hawaii at Manoa, Leahi Hosp.": "21.307 -157.858", 
        "Univ. of Miami AIDS CRS": "25.789 -80.226", 
        "University of Colorado Hospital CRS": "39.729 -104.832", 
        "Washington U CRS": "38.627 -90.199"
    }
}